Zimmer Biomet Holdings, Inc (NYSE:ZBH) announced plans to phase out its CPT Hip System by December.
The decision comes on the heels of a warning from the U.S. Food and Drug Administration (FDA), citing research showing a higher risk of postoperative fractures compared to similar hip replacement systems.
Patients with the CPT Hip System Femoral Stem 12/14 Neck Taper (CPT Hip System) face a 1.4% risk of thigh bone fractures. That’s higher than the 0.6%-1% fracture rates observed in similar devices.
Also Read: ...
